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Abstract
Purpose Despite the excellent capacity of the conventional
MRI to image brain tumours, problems remain in answer-
ing a number of critical diagnostic questions. To overcome
these diagnostic shortcomings, PET using radiolabeled
amino acids and perfusion-weighted imaging (PWI) are
currently under clinical evaluation. The role of amino acid
PET and PWI in different diagnostic challenges in brain
tumours is controversial.
Methods Based on the literature and experience of our
centres in correlative imaging with PWI and PET using O-
(2-[18F]fluoroethyl)-L-tyrosine or 3,4-dihydroxy-6-[18F]-
fluoro-L-phenylalanine, the current role and shortcomings
of amino acid PET and PWI in different diagnostic chal-
lenges in brain tumours are reviewed. Literature searches
were performed on PubMed, and additional literature was
retrieved from the reference lists of identified articles. In
particular, all studies in which amino acid PET was directly
compared with PWI were included.
Results PWI is more readily available, but requires sub-
stantial expertise and ismore sensitive to artifacts than amino
acid PET. At initial diagnosis, PWI and amino acid PET can
help to define a site for biopsy but amino acid PET appears to
be more powerful to define the tumor extent. Both methods
are helpful to differentiate progression or recurrence from
unspecific posttherapeutic changes. Assessment of thera-
peutic efficacy can be achieved especially with amino acid
PET, while the data with PWI are sparse.
Conclusion Both PWI and amino acid PET add valuable
diagnostic information to the conventional MRI in the
assessment of patients with brain tumours, but further
studies are necessary to explore the complementary nature
of these two methods.
Keywords Amino acid PET  18F-FET  18F-FDOPA 
Perfusion-weighted MRI  Relative cerebral blood volume
(rCBV)  Brain tumours
Introduction
Cerebral gliomas arising from different brain tissue types
are the most prevalent primary brain tumours with an
incidence of 5–6 in 100,000, apart from meningiomas [1].
Metastases in the brain originating from various peripheral
tumours are even more frequent tumours with an incidence
of 8-14/100.000 [2]. Histologically, gliomas are subdi-
vided into astrocytomas, oligodendrogliomas, ependymal
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tumours, and tumours of the choroids plexus. The classi-
fication of gliomas by the World Health Organization
(WHO) has been updated recently, combining now
molecular parameters, such as IDH mutation and 1p/19q
co-deletion with histology [3].
During the diagnostic process of brain lesions, it may be
crucial to differentiate brain tumours from benign lesions,
such as demyelination, hematoma, abscesses, and infarc-
tions which may appear similar on MRI. MRI is at present
the standard neuroimaging modality [4] owing to its
excellent soft-tissue contrast and spatial resolution. The
standard MRI for diagnostic imaging in brain tumours is
based on pre- and postcontrast T1-weighted images and
T2-weighted images, including fluid-attenuated inversion
recovery (FLAIR) images. However, there are limitations
in the standard MRI with regard to differentiating tumour
tissue from nonspecific changes, which is especially rele-
vant after therapy.
With positron emission tomography (PET), different
radioactively labelled tracers are injected to target various
metabolic and molecular pathways. This may add impor-
tant information especially in clinically challenging situa-
tions to improve diagnosis and therapy planning. Over the
past decades, PET with radiolabelled amino acids has
become a highly relevant diagnostic tool. Recent joint
recommendations of the Response Assessment in Neuro-
Oncology working group (RANO) and the European
Association for Neuro-Oncology (EANO) consider amino
acid PET as clinically helpful and suggest its use for
managing patients with brain tumours additionally to MRI
[5]. Meanwhile, advanced MRI methods, such as perfu-
sion-weighted imaging (PWI), are being evaluated in the
clinical setting and can provide complementary patho-
physiological information to the standard MRI. Based on
the experience of our centres in correlative imaging with
PWI and PET using O-(2-[18F]fluoroethyl)-L-tyrosine
(FET) or 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine
(FDOPA) in more than 500 brain tumour patients, this
review focuses on the clinical impact of amino acid PET
and PWI in adult patients during the workup of brain
tumours. Literature searches were performed on PubMed
using the search terms ‘‘brain tumours’’, ‘‘gliomas’’
‘‘positron emission tomography’’, ‘‘magnetic resonance
imaging’’, ‘‘Amino acids’’, ‘‘methionine’’, ‘‘FET,
‘‘FDOPA’’, ‘‘perfusion imaging’’, ‘‘PET’’, and ‘‘rCBV’’.
Additional literature was retrieved from the reference lists
of identified articles. Only papers in the English language
published until the end of 2016 were selected for review.
The references cited in the review were selected by the
authors with respect to the scientific quality, with prefer-
ence to more recent publications, and relevance of the
papers in the field according to the personal experience of
the authors. In particular, all studies were included in
which amino acid PET was directly compared with PWI.
These studies are summarized in Table 1. The performance
of amino acid PET and PWI is discussed with respect to
differential diagnosis of brain lesions, tumor delineation
and biopsy guidance as well as therapy monitoring and
discrimination between tumour progression or recurrence
and treatment-related changes.
PET using radiolabelled amino acids
Amino acids present several advantages over 18F-2-fluoro-
2-deoxy-D-glucose (FDG) and are now regarded as the
tracers of choice for PET imaging of brain tumours [6].
The first radiopharmaceutical of this class to be used
clinically was 11C-methyl-L-methionine (MET), an iso-
topically labelled methionine made from 11CH3-I alkyla-
tion of homocysteine [7]. Data on the clinical usefulness of
MET in brain tumours have been collected for more than
30 years; however, due to the short half-life of 11C
(20 min), which limits the use of MET to centres equipped
with an onsite cyclotron, the interest around fluorinated
compounds has grown significantly in the recent past. The
two most popular amino acid PET radiopharmaceuticals
labelled with 18F (109.8 min half-life) are O-(2-[18F]fluo-
roethyl)-L-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-flu-
oro-L-phenylalanine (FDOPA). FET is a tyrosine
derivative, which is synthesized with high yield by a two-
step fluoroethylation of tyrosine [8]. FDOPA is an ana-
logue of the non-proteinogenic amino acid L-DOPA, which
has historically been synthesized via electrophilic substi-
tution. However, because of isomeric impurities, low
specific activity, low radiochemical yield, and precursor
toxicity, this process has been later abandoned for nucle-
ophilic substitution [9, 10]. The molecular structures of the
abovementioned synthetic amino acids are shown in Fig. 1.
With the exception of MET, these radiolabelled amino
acids are not incorporated into proteins [11]; nevertheless,
their uptake mechanisms are highly efficient, leading to very
favourable tumour-to-background ratios. The uptake of
radiolabelled amino acids is based on the expression of the
Na?-independent large neutral amino acid transporters on
the cell surface of tumour cells, namely, LAT1 and LAT2.
This mechanism is independent from blood–brain barrier
permeability; therefore, amino acid probes are able to depict
non contrast-enhancing brain tumour regions, which are a
clear advantage over other PET tracers, such as 30-deoxy-30-
[18F]fluorothymidine (FLT) [12] and 18F-Fluorocholine
(FCH) [13]. MET and FDOPA uptakes are thought to be
largely due to LAT1 [14, 15], while FET is transported by
both LAT1 and LAT2 [16]. A recent study showed that the
retention of FET into cells is due to an asymmetric intra- and
extracellular recognition of LAT1, with consequent poor
efflux from the cell back to the extracellular space [17].
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No relevant differences between available radiolabelled
amino acids have been shown in terms of tumor to brain
contrast [18–21]. However, some differences exist with
regard to tracer biodistribution in the brain and the time-
activity curves of tracer uptake. FDOPA is a substrate for
the enzyme aromatic amino acid decarboxylase in
dopaminergic neurons [22]; this is responsible for FDOPA
prominent uptake by the basal ganglia which might inter-
fere with tumour delineation [23]. In addition, available
data suggest that FET kinetics may add additional biolog-
ical information, which may be helpful for glioma grading
[24, 25], the differentiation of both glioma and brain
metastasis recurrence from radiation-induced changes
[26–28] or the prognostication of untreated gliomas
[29, 30]. Although amino acid PET shows high accuracy
for the detection of brain tumours [31], tracer uptake in
non-neoplastic brain lesions has to be taken into account.
Thus, unspecific amino acid uptake in the brain has been
reported in multiple sclerosis and other inflammatory
lesions, vascular malformations, ischemic lesions, hema-
tomas, etc [32–36]. Moreover, amino acid PET may be
negative in a significant proportion of low-grade gliomas
[37, 38].
MRI and MR perfusion imaging
MRI is the method of choice for anatomical imaging in
patients suspicious for brain tumours as well as during the
course of therapy in brain tumour patients due to its
excellent soft-tissue characterization, high resolution, and
easy multiplanar reconstruction. The standard MRI includes
pre- and postcontrast T1-weighted sequences as well as T2-
weighted sequences possibly with FLAIR sequences
[4, 39–41]. MRI has a high sensitivity to detect brain lesions
due to its excellent soft-tissue contrast, but hyperintense
signal in T2-weighted images may also be caused by peri-
tumoural oedema. In tumours with diffuse cell infiltration, a
clear demarcation of tumour from peritumoural changes
may not be possible. In contrast, enhancement in T1-
weighted images indicates a disruption of the blood–brain
barrier (BBB) and is typical but not specific for malignant
tumours. Particularly, treatment-related changes after sur-
gery, radio-, or chemotherapy of brain tumours may also
cause contrast enhancement and be challenging to differ-
entiate from tumour recurrence [4, 42, 43].
PWI is an advanced MRI method which provides infor-
mation on brain hemodynamics in addition to the
Table 1 Studies comparing amino acid PET and PWI
First author and year Patient group PET
tracer
No of
patients
Results
Berntsson 2013 [83] Untreated low grade
glioma
MET 24 Spatial overlap of MET hotspots and PWI max but no correlation of
rCBV and MET uptake
Cicone 2015 [23] Recurrent/progressive
glioma
FDOPA 44 Higher tumor to brain contrast in FDOPA PET and larger tumor
volumes than in rCBV maps, poor spatial congruence of FDOPA
and rCBV
Cicone 2015 [147] Recurrent metastasis
versus radionecrosis
FDOPA 42 Better performance of FDOPA PET than rCBV in differentiating
recurrent metastasis from radionecrosis
Dandois 2010 [140] Recurrent glioma versus
radionecrosis
MET 28 Equal performance of rCBV and MET PET in differentiation of tumor
recurrence versus radionecrosis
D’souza 2014 [133] Recurrent glioma versus
radionecrosis
MET 29 rCBV and MET uptake equally useful to differentiate recurrence
versus radionecrosis
Filss 2014 [79] Primary and recurrent
gliomas
FET 56 Higher tumor to brain contrast in FET PET and larger tumor volumes
than in rCBV maps, poor spatial congruence of FET and rCBV
Henriksen 2016 [80] Pretreated gliomas FET 41 Higher tumor to brain contrast in FET PET and larger tumor volumes
than in rCBV maps, poor spatial congruence of FET and rCBV
Kim 2010 [141] Recurrent glioma versus
radionecrosis
MET 10 Equal performance of rCBV and MET PET in differentiation of tumor
recurrence versus radionecrosis
Rossi Espagnet 2016
[118]
Pretreated low grade
gliomas
FDOPA 12 No correlation of rCBV and FDOPA uptake
Sadeghi 2006 [78] Primary and recurrent
gliomas
MET 18 rCBV and MET uptake strongly correlated
Sadeghi 2007 [77] Primary and recurrent
gliomas
MET 14 rCBV and MET equivalent in the assessment of tumor infiltration
Tietze 2015 [82] Untreated gliomas MET 13 rCBV helpful in HGG but not useful in LGG in contrast to MET PET
Go¨ttler 2017 [81] Untreated gliomas FET 30 Moderate overlap of tumor volumes in FET PET and rCBV maps
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conventional MRI [44, 45]. Important parameters which can
be determined by PWI are the relative cerebral blood vol-
ume (rCBV), relative cerebral blood flow (rCBF), and the
relative mean transit time (MTT) [45–47]. PWI is usually
performed with paramagnetic gadolinium as an exogenous
contrast agent which causes an apparent signal increase in
T1-weighted images and a signal loss in T2 or T2*-
weighted images. Dynamic susceptibility contrast MRI
(DSC) based on T2*weighted imaging using a 2D echo
planar imaging (EPI) is the most widely used method for
PWI [44, 45]. Blood–brain barrier leakage may be a source
of error with DSC which can be reduced by a pre-bolus of
contrast agent prior to acquisition as well as post-processing
techniques for leakage correction [45, 48]. Another method,
dynamic contrast-enhanced MRI (DCE) is also based on a
short bolus of contrast agent and measures changes in T1-
weighted images over time. DCE is less prone to artifacts,
but signal changes are smaller compared with DSC which
results in rather low signal-to-noise ratio in the calculated
parametric maps. Therefore, DCE is infrequently used in
clinical practice and not included in the standard software of
most scanners [47]. Recently, however, multi-echo
sequences have been proposed to correct for leakage effect
for DSC [49] and to extract T1 dynamics [50]. By com-
bining DSC and DCE in a GRE and SE sequence (GESE)
[51], further information about vasculature can be obtained
[52]. Such parametric images can also be used to track
therapy response in brain tumours to antiangiogenic agents
[53]. Moreover, CBF can be measured by arterial spin
labeling (ASL) using magnetically labelled water as
endogenous tracer which avoids an exogenous contrast
agent but the long acquisition time is a disadvantage [45].
Amino acid PET and MR perfusion imaging
for tumour differential diagnosis
If a brain lesion of unclear origin is detected in a patient, it
is of paramount clinical importance to differentiate
between a neoplastic or non-neoplastic process. MRI with
gadolinium-based contrast agents provides a number of
imaging features, which may allow a differential diagnosis
in a considerable fraction of the lesions. The imaging
findings of brain tumours may include diffusely delineated
tumour margins, perifocal oedema, central necrosis, pres-
ence of cystic formations, and a ring-enhancing pattern of
contrast enhancement. The reliability of these signs, how-
ever, is limited. PWI can be helpful in special situations,
for example, to differentiate brain abscesses from malig-
nant gliomas or brain metastases [54].
PET using radiolabelled amino acids generally shows
higher uptake in neoplastic lesions than in non-neoplastic
lesions and increased amino acid uptake in benign lesions
is rare. Nevertheless, false-positive uptake of MET, FET
and FDOPA has been reported in infectious lesions (e.g., in
brain abscesses), demyelinating lesions, ischemic stroke, in
cerebral haemorrhages, and also in patients with status
epilepticus or seizure clusters [34, 55]. Regarding differ-
ential diagnosis, a meta-analysis evaluated 462 patients
with newly diagnosed brain lesions suspected of being
brain tumours and revealed a pooled sensitivity of 82% and
specificity of 76% for the correct diagnosis of primary
brain tumours [56] based on a threshold of the maximum
tumour/brain ratio of 2.1. A subsequent study evaluated
174 patients with newly diagnosed brain lesions and
reported a high specificity (92%), but a lower sensitivity
(57%) for the differentiation of neoplastic from non-neo-
plastic tissue [35]. Nevertheless, in that study, a maximum
tumour/brain ratio of 2.5 or more yielded a very high
positive predictive value for neoplastic tissue of 98%.
Comparative studies between amino acid PET and PWI in
this field are not yet available in the literature.
In summary, imaging findings from both the conven-
tional MRI and PWI as well as amino acid PET may add
Fig. 1 Molecular structure of 11C-methyl-L-methionine (MET), O-
(2-[18F]fluoroethyl)-L-tyrosine (FET), and 3,4-dihydroxy-6-[18F]-flu-
oro-L-phenylalanine (FDOPA)
212 Clin Transl Imaging (2017) 5:209–223
123
valuable additional information for the characterization of
equivocal brain lesions, but they lack sufficient diagnostic
accuracy. Therefore, a histological evaluation of these
suspicious brain lesions by biopsy or resection is frequently
indispensable.
Amino acid PET and MR perfusion imaging
for imaging of tumour extent and biopsy guidance
The diagnostic performance of the conventional MRI to depict
the true extent of cerebral gliomas and to detect the most
aggressive areas in inhomogeneous gliomas is limited and
especially difficult in gliomas showing no contrast enhance-
ment.Representative tissue samplesofbrain tumours arevitally
important for the correct histological tumour diagnosis and
grading, evaluation of molecular markers (e.g., IDHmutation),
prognostication, and treatment decisions. Particularly, in infil-
trating brain tumours with enhancing and non-enhancing
tumour portions, the correct delineation of tumour extent and
the identificationof themostmalignant parts canbe challenging
and may result in under-diagnosis.
For PET, a number of studies have explored the spatial
correlation of histopathological findings with amino acid
uptake and provided evidence that the solid tumour mass of
gliomas typically shows increased amino acid uptake and
detects tumour extent more reliably than standard MRI
[57–62] (Fig. 2). The improved delineation of tumor extent
is one of the most important advances in brain tumor
diagnostics provided by amino acid PET, but it has to be
considered that a fraction of approx. 5% of all gliomas,
especially low-grade gliomas, do not accumulate radiola-
beled amino acids [35]. Nevertheless, amino acid PET is
clearly superior to the standard MRI and the property of
amino acid PET to detect tumour extent has been used in
many studies for treatment planning, especially in tumor
resection and radiation therapy [63–73]. In contrast, only a
few studies have investigated the diagnostic value of PWI
for the detection of brain tumour extent [74, 75]. Those
studies observed elevated rCBV beyond the contrast-en-
hancing volume indicating that tumour infiltration might
also be detected by PWI. A biopsy-controlled study
reported that rCBV regionally correlates with both cell and
microvessel density within gliomas [76]. Another biopsy-
controlled study demonstrated that rCBV correlated with
cell proliferation in high-grade gliomas but a correlation of
rCBV with tumour cell density could not be confirmed
[74]. These studies suggest that rCBV mapping allows only
very limited conclusions with regard to tumor extension.
While some earlier studies comparing amino acid uptake
and rCBV observed similarities between MET uptake and
rCBV abnormalities in gliomas [77, 78], more recent
publications reported on considerably larger tumour vol-
umes in amino acid PET than in rCBV maps and a poor
spatial overlap [23, 79–82] (Figs. 3, 4; Table 1). Further-
more, rCBV mapping exhibited a lower lesion-to-brain
contrast and a highly variable background noise as com-
pared with amino acid PET [23, 79]. Another hybrid PET/
MRI study reported that artifacts due to susceptibility dif-
ferences between bone and air, iron accumulations, and
blood degradation products hampered interpretation of the
rCBV signal in the tumour area in 56% of the patients [80].
Thus, amino acid PET appears to be superior to rCBV
mapping for the detection of the extent of cerebral gliomas
and interpretation of rCBV maps appears to be more
challenging than with amino acid PET.
Regarding biopsy guidance, parametric rCBV maps
have been used to target the most malignant tumour parts,
since the rCBV may indicate tumour parts with neovas-
cularization. Some studies directly comparing local hot
spots in amino acid PET and rCBV maps in gliomas
reported on a spatial colocalization of local maxima
[77, 83], but other studies observed considerable spatial
Fig. 2 Comparison of MRI and FET PET of patient with an
anaplastic astrocytoma WHO grade III. Contrast-enhanced T1-
weighted MRI (A) shows pathological contrast enhancement in the
vicinity of the posterior horn of the right ventricle and corresponding
signal abnormalities in the T2-weighted image (B). FET PET
(C) detects metabolically active tumor tissue extending beyond the
abnormalities in MRI
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distances of the local maxima in both methods [23, 79]
(Table 1; Figs. 5, 6). It remains unclear whether the spatial
position of the local maxima of amino acid uptake or rCBV
in gliomas correspond to the most aggressive part of the
tumour and further comparative studies are needed to
investigate this aspect. Amino acid has been shown to be a
very sensitive method to identify metabolic hot spots in
gliomas for biopsy guidance [84–86]. In low-grade glio-
mas, a sensitivity of 72–79% has been reported for FET
PET to identify a hot spot for biopsy guidance [35, 84].
Furthermore, the evaluation of kinetic parameters such as
time-to-peak values or the curve pattern of FET uptake
derived from dynamic PET scans in gliomas appears to be
helpful to identify areas of malignant progression and
unfavourable prognosis [29, 30, 37, 87–89]. These data
highlight the potential of amino acid PET for the identifi-
cation of metabolically active areas in brain tumours to
target biopsies.
Fig. 3 Hybrid PET/MRI of patient with an astrocytoma WHO grade
II. Contrast-enhanced T1-weighted MR imaging (A) shows a small
area with contrast enhancement in the left frontal lobe while FET PET
(C) detects a large tumor extending within the area of signal
abnormality in the FLAIR image (B). Tumor depiction in rCBV map
(D) is difficult because of a poor tumor to brain contrast
Fig. 4 Comparison between MRI and 18F-DOPA PET of a patient
with an astrocytoma. A non-enhancing (A), FLAIR positive (B) left
temporo-thalamic lesion is seen, corresponding to 18F-DOPA uptake
(C) above the physiological radioactivity of the basal ganglia. In
contrast, rCBV map (D) fails to show increased tumor perfusion. An
anaplastic transformation was observed 3 months later, characterized
by contrast enhancement and increased rCBV (images not shown)
Fig. 5 Hybrid PET/MRI of patient
with a glioblastoma WHO grade IV.
Contrast-enhanced T1-weighted MR
imaging (A) shows a small area with
contrast enhancement in right parietal
lobe and corresponding signal
abnormality in the FLAIR image
(B) which shows focal tracer uptake in
FET PET (C) and correspondingly
increased rCBV (D)
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In summary, both amino acid PET and PWI may be
helpful for biopsy guidance, but the more reliable method
to delineate the glioma extent seems to be amino acid PET.
Amino acid PET and MR perfusion imaging
for tumour grading and prognosis
The evaluation of brain tumor histology is the method of
choice for tumour grading and decisive for treatment
planning. Tissue samples, however, are sometimes not
representative of the most aggressive tumor parts and
varying interpretation by different neuropathologists may
cause uncertainties. Therefore, an agreement of
histopathology with non-invasive imaging parameters may
support the clinical decision-making.
Most studies using amino acid PET in gliomas come to
the conclusion that amino acid uptake does not allow a
reliable prediction of tumour grade owing to highly vari-
able amino acid uptake in gliomas of different WHO
grades [90]. Glioma grading is further affected by high
amino acid uptake in oligodendrogliomas despite the better
prognosis of these tumours in comparison with astrocy-
tomas of the same grade [91–94]. Therefore, static amino
acid PET achieves only an accuracy of 70–80% for pre-
dicting a high-grade gliomas [31, 35, 93, 95]. Analysis of
FET kinetics may slightly improve the discrimination of
high-grade and low-grade glioma in both primary tumours
and recurrent tumours [24, 25, 29, 88, 93, 96, 97].
The significance of PWI for tumour grading has been
investigated in many studies with variable results
[54, 98–101]. One study reported no difference between
PWI and contrast-enhanced MRI [102]. Especially, low-
grade oligodendroglioma may exhibit increased rCBV
despite an excellent prognosis similar to the findings with
amino acid PET [103]. A prospective study with 129
patients achieved a high accuracy in tumour grading with
the conventional MRI based on the parameters contrast
enhancement and necrosis (sensitivity 96%; specificity
70%) and the results did not improve when including PWI
[104]. In contrast, a recent meta-analysis came to the
conclusion that differentiation of low- and high-grade
gliomas was improved by PWI compared with the con-
ventional MRI [105].
While the prognostic significance of amino acid uptake
ratios in gliomas remains questionable, recent studies
indicate that the ‘‘biological tumour volume’’ (BTV) as
determined by amino acid PET represents an independent
prognostic factor [106–108]. In addition, amino acid PET
seems to be useful to predict survival in patients with low-
grade gliomas [38, 109–113]. In patients with newly
diagnosed low-grade glioma, FET PET together with
anatomical MR has been reported to be a significant factor
to predict outcome [38]. In low-grade gliomas, particularly,
FET kinetics may be useful to locate regions of malignant
transformation and poor prognosis [30, 37, 87, 89, 114].
Using PWI, some studies have reported a relationship
between rCBV in gliomas and overall survival [115–117].
A first study comparing FDOPA PET and rCBV in a small
cohort of low-grade gliomas showed a better correlation of
PET parameters with outcome than rCBV [118].
In summary, amino acid PET and PWI can support non-
invasive grading and prediction of outcome in gliomas.
However, the final diagnosis is based on histology of
tumour tissue.
Amino acid PET and MR perfusion imaging
for the diagnosis of tumour recurrence/progression
The distinction between tumour recurrence or progression
and treatment-related changes represents a major challenge
for the conventional MRI, since subacute and late types of
treatment-induced injury, namely, pseudoprogression and
radionecrosis, are characterized by an increase of contrast
enhancement, indistinguishable from tumor progression
[119]. Pseudoprogression usually occurs within the first
12 weeks after irradiation in 10–30% of patients with high-
grade gliomas treated with concomitant temozolomide
[120]. A recent study using FET PET showed an excellent
overall accuracy of 96% (sensitivity, 100%; specificity,
91%) in discriminating pseudoprogression from early
progression in 22 patients with glioblastoma [26]. Studies
assessing pseudoprogression with perfusion-weighted MRI
are more numerous though less promising, probably
because rCBV is influenced by disruption of the BBB
[121–125]. A recent meta-analysis yielded a pooled sen-
sitivity of 89% and a pooled specificity of 80% for DSC
perfusion-weighted imaging in this clinical setting [126].
Diagnostic accuracy of DCE perfusion-weighted images
has been reported in the same range of values [127].
Fig. 6 Hybrid PET/MRI of a patient with an oligoastrocytoma WHO
grade III. Contrast-enhanced T1-weighted MR imaging (A) shows a
large mass in the right parietal lobe showing no contrast enhance-
ment. FET PET (B) detects a local maximum in the paramedian part
of the tumour which is not obvious in the rCBV map (C)
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More data are available on the performances of amino
acid PET to differentiate tumor recurrence from treatment-
related changes in the later stage of the disease. Earlier
experiences with FET showed the superiority of amino acid
PET over the standard MRI in this setting [128]. In a large
heterogeneous cohort of 124 patients with gliomas of dif-
ferent grades and histologies, Galldiks and coworkers
found an accuracy of 93% (sensitivity = 93%, speci-
ficity = 100%) in differentiating neoplastic disease from
treatment-related changes by combining static and dynamic
information from FET scans [129]. In a similar-sized study
of 110 patients, performances of FDOPA PET were
slightly lower, with an accuracy of 82% (sensitiv-
ity = 89.6%, specificity = 72.4%) [130]. The results of
these two latter studies, however, are hardly comparable
because of the different methods of image analysis and of
an unbalanced percentage of recurrent diseases and
unspecific changes in the two patient cohorts. Another
study using F-DOPA PET in a smaller population of 35
patients showed an overall accuracy of 97% in the same
setting [131]. Using MET PET, Terakawa and coworkers
studied a heterogeneous sample of 26 gliomas showing
both sensitivity and specificity of 75% for discriminating
between tumour recurrence and radiation necrosis [132]. In
a later study, D’Souza and coworkers found an overall
accuracy of 89.6% (sensitivity = 94.7%, speci-
ficity = 80%) in 29 patients with high-grade gliomas
[133]. The same group has recently extended these results
to a larger cohort of 64 tumours from various histologies,
particularly emphasizing the higher accuracy of MET over
FDG PET in low-grade gliomas (sensitivity = 93.3%
specificity = 90%) [134].
The performances of PWI techniques (either DSC or
DCE) in correct classification of late treatment-related
changes were assessed by several studies, resulting in
cumulated sensitivity and specificity of 90 and 88%,
respectively [126, 135–138]. Of note, the presence of
haemorrhage, image distortion, and susceptibility artifacts
limits the applicability of DSC perfusion MR images in a
non-negligible number of cases [136, 139]. In some of
these non-interpretable cases, however, DCE MRI seems to
overcome the limitations of DSC images [139]. Some
studies have compared amino acid PET vs PWI and
reported on a similar diagnostic power of PWI in this
setting, but the number of patients in those studies is rel-
atively small, so that currently, no reliable conclusion can
be drawn [133, 140, 141] (Table 1).
Amino acid PET imaging has also proved to be valuable
in discriminating between tumour recurrence and
radionecrosis in brain metastases. Radionecrosis occurs
after a median of 12 months after radiation treatment and
its incidence varies depending on the local radiation dose
[142, 143]. Using FET PET, the combination of static
imaging with dynamic information yielded an overall
accuracy ranging between 87 and 93% in two different
patient cohorts with a total of 76 [28, 144] and 34 brain
metastases, respectively [145]. Encouraging results were
also obtained with FDOPA in 83 brain metastases using a
qualitative approach for image analysis (sensitiv-
ity = 81.3%, specificity = 84.3%) [146] and in another
study in 50 brain metastases using a semiquantitative
approach for image analysis (sensitivity = 90%, speci-
ficity = 92.3%, accuracy = 91.3%) [147]. In addition, this
latter paper reports on the only available direct comparison
between amino acid PET and PWI in this setting, demon-
strating better performances of amino acid PET in classi-
fying indeterminate enlarging brain metastases after
radiation treatment (37 lesions available for comparison,
91.9 vs 75.6% overall accuracy for FDOPA and DSC PWI,
respectively). Recent data from the same group confirmed
the superior performances of F-DOPA PET over MRI
including DSC PWI techniques in assessing the evolution
over time of predominantly radionecrotic brain metastases
after stereotactic radiosurgery [148]. As regards MET,
available data suggest moderately lower discriminating
power (sensitivity = 79%, specificity = 75%) in 51 sec-
ondary lesions [132]. PWI holds promises in the setting of
brain metastases as well, albeit the number of available
studies and patients included is limited [149–151]. At
present, a combined approach for differential diagnosis is
to be encouraged, as already put in practice by single
specialized centers [152, 153].
In summary, available literature shows that both amino
acid PET and perfusion-weighted MRI are useful aids to
the differential diagnosis between tumour progression and
treatment-related changes in both gliomas and brain
metastases; hence, an integrated approach is advised.
Amino acid PET and MR perfusion imaging
for treatment monitoring of brain tumours
The early detection of tumour response to therapy is of
great importance for the optimization of individual tumor
therapy.
In the context of both chemoradiation with temozolo-
mide and temozolomide monotherapy, the reliability of
treatment monitoring using MET was shown in a cohort of
15 patients with heterogeneous tumour histologies and
prior treatment history [154]. Using FET PET, Piroth et al.
demonstrated that an early (7–10 days after treatment
completion) [10% reduction of TBRmax from baseline
was predictor of disease free survival and overall survival
in a homogeneous population of 22 patients with
glioblastoma, whereas no such prognostic significance
could be found for changes in contrast enhancement
[107, 155]. In addition, FET PET demonstrated the ability
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to stratify responses to temozolomide several months ear-
lier than MRI in 11 patients with progressive non-en-
hancing low-grade gliomas [156]. More recently, a
multicenter study demonstrated that changes of tumour
volume in amino acid PET were superior to MRI for
evaluating responses to temozolomide in WHO grade II
glioma and to predict progression-free survival [157].
Amino acid PET tracers were also tested in the response
evaluation of antiangiogenic treatments. A special problem
represents the so-called ‘‘pseudoresponse’’ during antian-
giogenic treatment. Here, a fast reduction of contrast
enhancement in MRI may hide the underlying growth of
the non-enhancing, T2-positive, portion of the tumour. The
sensitivity and reliability of the conventional MRI in this
setting is limited [4]. In a cohort of 11 patients under
bevacizumab treatment, a significant discrepancy between
FET uptake and RANO criteria was observed in 4/11
patients suggesting that FET can detect treatment failure
earlier than the conventional MRI [158]. Similar findings
were subsequently reported in an independent cohort of ten
patients treated with bevacizumab [159]. Using FDOPA
PET, metabolically active tumour volume measured as
early as 2 weeks after therapy initiation, as well as tumour
volume changes during therapy, was also found to be
strong predictors of survival in a larger cohort of 30
patients under bevacizumab/irinotecan [160]. In that study,
there were eight (26%) discordant cases and PET outper-
formed MRI-based RANO criteria.
A few studies have evaluated the performances of PWI
in early treatment assessment. Unfortunately, up to now, no
direct comparison with amino acid PET exists. Sawlani and
colleagues have retrospectively evaluated 16 patients with
glioblastoma undergoing bevacizumab treatment, deriving
an index of local perfusion (hyperperfusion volume, HPV)
which correlated with time-to-progression [161]. The lar-
gest study available included 36 patients with high-grade
gliomas who underwent perfusion-weighted sequences in
addition to standard MRI before and during bevacizumab
treatment [162]. In that study, an improved survival was
obtained in patients with low tumour rCBV either before or
during treatment. In contrast, a study evaluating the effect
of cediranib, a pan-VEGF receptor tyrosine kinase inhi-
bitor, showed that an increase in tumour perfusion was
predictive for better outcome [163], according to the
‘‘vascular normalization hypothesis’’ [164].
In summary, amino acid PET shows convincing results
concerning sensitive and specific assessment of treatment
response at an early stage during chemotherapy or antian-
giogenic therapy. In contrast, despite widespread avail-
ability, PWI has so far only been investigated to a small
extent in this area and further investigations are needed.
Conclusion
In contrast to amino acid PET, most neuro oncological
centres have access to PWI which, however, requires a great
deal of experience to ensure meaningful assessment are
made and therefore is not always used efficiently. Another
limitation of PWI is the lack of standardization of the
methods used and in data processing. Amino acid PET is as
yet not available in every centre, but the method is rapidly
spreading not only because of its diagnostic power but also
because of its robustness and the fact that interpreting amino
acid PET may be easier for clinicians involved in neuro
oncology than PWI owing to the higher tumour to back-
ground contrast andmore homogenous background. The two
methods are based on different biochemical-physiological
mechanisms but can provide diagnostic information beyond
the conventional MRI depending on the clinical question.
At initial diagnosis of space occupying brain lesions, a
relatively reliable differential diagnosis can be achieved by
the use of the conventional MRI and PWI, and amino acid
PET appears necessary in equivocal situations only. In the
case of highly suspicious lesions, both methods can help to
define a site for biopsy to obtain a meaningful histology.
Table 2 Contribution of MRI,
amino acid PET, and PWI in
brain tumour diagnosis
MRI PWI Amino acid PET (MET, FET, FDOPA)
Differential diagnosis ?? – ?
Tumour extent ? ? ??
Biopsy guidance ? ?? ??
Grading ?? ?? ?a
Prognosis ? ?? ?
Recurrence ? ?? ??
Therapy monitoring ? ? ??
It reflects the personal opinion of the authors on the basis of this literature review and their personal
experience in the field
??, high diagnostic value; ?, limited diagnostic value; –, not helpful
a Increased diagnostic value when using dynamic FET PET
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Amino acid PET, on the other hand, appears to be more
powerful to define the tumor extent (Table 2). If, after the
primary therapy of the tumour, there is a suspicion of
progression or recurrence, both methods are helpful to
differentiate these from unspecific posttherapeutic changes.
An early and sensitive assessment of therapeutic efficacy
can be achieved especially with amino acid PET, while the
data with PWI are sparse despite a broad availability. To
further improve the diagnostics of brain tumours, it seems
necessary to explore the complementary nature of these
two methods in further studies. This is not only in the
interest of the patients, but also of society, since the
treatment costs for this disease are extremely high.
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